Hallmarks of Aging Part 1: Genomic Instability, Epigenetic Alterations, and Loss of Proteostasis

Evidence Quality Summary

What Is Genomic Instability?

Genomic instability refers to the increased tendency of the genome to acquire mutations and structural alterations during the life of a cell or organism. It is the first hallmark of aging proposed by López-Otín and colleagues in their seminal 2013 framework, updated in 2023. The concept encompasses a broad spectrum of DNA damage types, including point mutations, deletions, insertions, chromosomal translocations, and telomere shortening. This damage arises from both endogenous sources—such as reactive oxygen species (ROS) produced during normal metabolism, replication errors, and spontaneous hydrolysis—and exogenous sources including ultraviolet radiation, ionizing radiation, and environmental chemicals.

The human genome sustains tens of thousands of DNA lesions per cell per day. Under normal conditions, a sophisticated network of DNA repair pathways—including base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), and double-strand break repair via homologous recombination (HR) or non-homologous end joining (NHEJ)—corrects the vast majority of these lesions. With advancing age, the efficiency of these repair systems declines, leading to the progressive accumulation of unrepaired damage. This accumulation is particularly pronounced in post-mitotic tissues such as neurons and cardiac muscle, where damaged cells cannot be replaced through division.

Research in this area has been extensively reviewed. For instance, Hoeijmakers (2009) provided a comprehensive overview of DNA damage and repair mechanisms in the context of aging, published in the New England Journal of Medicine. The causal role of genomic instability in aging is strongly supported by the existence of progeroid syndromes—rare genetic disorders that accelerate aging—caused by mutations in DNA repair genes. Examples include Werner syndrome (mutations in the WRN helicase), Bloom syndrome (BLM helicase), and xeroderma pigmentosum (various NER pathway genes). These conditions demonstrate that impaired DNA repair capacity directly accelerates the appearance of aging phenotypes.

What Are Epigenetic Alterations?

Epigenetic alterations are changes in gene expression patterns that occur without alterations to the underlying DNA sequence. These changes involve three primary mechanisms: DNA methylation, histone post-translational modifications, and chromatin remodeling. During aging, the epigenome undergoes profound remodeling, characterized by global hypomethylation (loss of methyl groups across the genome) and localized hypermethylation at specific CpG islands, particularly those associated with tumor suppressor genes and developmental regulators.

Histone modifications also change with age. Research has documented alterations in the levels of histone acetylation, methylation, and phosphorylation, which collectively influence chromatin accessibility and gene expression. For example, the loss of heterochromatin—a tightly packed form of DNA—is a well-documented feature of aging in multiple species. This heterochromatin loss leads to the inappropriate expression of normally silenced genomic regions, including transposable elements and repetitive sequences.

The development of "epigenetic clocks"—mathematical models that predict chronological age based on DNA methylation patterns at specific CpG sites—has been a major advance in the field. Horvath (2013) developed a multi-tissue epigenetic clock that accurately predicts age across multiple human tissues, published in Genome Biology. More recently, second-generation clocks such as PhenoAge and GrimAge incorporate clinical biomarkers and mortality risk, providing measures of biological rather than chronological age. However, it remains debated whether these clocks reflect a causal driver of aging or merely a consequence of other aging processes.

Interventions that modulate the epigenome are under active investigation. Caloric restriction, for instance, has been shown to attenuate age-related epigenetic changes in rodents. Pharmacological approaches include histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors, though these agents are primarily studied in cancer contexts. Partial reprogramming using Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC) has shown promise in reversing some age-related epigenetic marks in cell culture and in vivo models, but concerns about tumorigenesis and safety remain significant.

What Is Loss of Proteostasis?

Loss of proteostasis refers to the progressive failure of the cellular systems that maintain protein homeostasis—the correct folding, trafficking, and degradation of proteins. Proteins are synthesized as linear chains of amino acids that must fold into precise three-dimensional structures to function properly. This folding process is error-prone, and misfolded proteins can aggregate into toxic species that disrupt cellular function. To counter this, cells have evolved an integrated network of quality control mechanisms.

The proteostasis network comprises three main components: molecular chaperones that assist in protein folding, the ubiquitin-proteasome system (UPS) that degrades short-lived and misfolded proteins, and the autophagy-lysosome pathway that clears larger protein aggregates and damaged organelles. The unfolded protein response (UPR) in the endoplasmic reticulum (ER) and the cytosolic heat shock response coordinate the expression of chaperones and proteolytic machinery in response to proteotoxic stress.

With aging, the capacity of these systems declines. Chaperone expression decreases, proteasome activity diminishes, and autophagic flux becomes impaired. The resulting accumulation of misfolded and aggregated proteins is a hallmark of many age-related neurodegenerative diseases, including Alzheimer's disease (amyloid-beta plaques and tau tangles), Parkinson's disease (alpha-synuclein Lewy bodies), and Huntington's disease (huntingtin aggregates). However, protein aggregation is not limited to disease states—even normal aging is associated with increased protein insolubility and aggregation.

Research in model organisms has established causal links between proteostasis capacity and lifespan. For example, overexpression of heat shock proteins extends lifespan in C. elegans and Drosophila. Conversely, genetic disruption of autophagy shortens lifespan and accelerates aging phenotypes in mice. Pharmacological interventions that enhance proteostasis, such as rapamycin (which induces autophagy via mTOR inhibition) and spermidine (a polyamine that promotes autophagy), have been shown to extend lifespan in multiple model organisms.

Proposed Mechanisms of Action

The three hallmarks discussed—genomic instability, epigenetic alterations, and loss of proteostasis—are not independent processes but rather interact through multiple feedback loops. DNA damage can directly influence the epigenome by altering the recruitment of chromatin-modifying enzymes to sites of damage. For instance, the DNA damage response (DDR) pathway has been reported to trigger local changes in histone modifications and DNA methylation. Conversely, epigenetic changes can influence DNA repair efficiency by modulating the accessibility of damaged DNA to repair machinery.

Loss of proteostasis contributes to genomic instability through several mechanisms. Misfolded proteins can impair the function of DNA repair enzymes, while the accumulation of protein aggregates can sequester critical repair factors. Additionally, proteotoxic stress can activate inflammatory signaling pathways that generate ROS, further damaging DNA. The interplay between these hallmarks creates a vicious cycle that accelerates the aging process.

The concept of "antagonistic pleiotropy" is relevant here: some processes that are beneficial early in life become detrimental with age. For example, the DNA damage response is essential for maintaining genome integrity in young organisms, but chronic DDR activation in aging cells can drive cellular senescence and inflammation. Similarly, epigenetic changes that silence transposable elements are protective in early life but may become dysregulated with age.

Preclinical Research Findings

The majority of evidence for these hallmarks comes from preclinical studies. In cell culture models, replicative senescence—the finite proliferative capacity of human cells first described by Hayflick and Moorhead in 1961—is associated with accumulating DNA damage, epigenetic changes, and proteostatic decline. Primary human fibroblasts, for instance, show progressive telomere shortening, altered DNA methylation patterns, and reduced proteasome activity as they approach senescence.

In vivo studies in model organisms have provided causal evidence. Mice with targeted mutations in DNA repair genes (e.g., Ercc1, Xpa, Atm) exhibit accelerated aging phenotypes, including neurodegeneration, kyphosis, and shortened lifespan. Similarly, mice lacking key autophagy genes (e.g., Atg5, Atg7) develop neurodegenerative and metabolic abnormalities. These studies have been reviewed extensively in the aging literature.

Epigenetic interventions have shown promise in animal models. Partial reprogramming using cyclic expression of Yamanaka factors in mice has been reported to reverse some age-related phenotypes and extend lifespan in progeroid mouse models. However, these findings have been met with caution due to the risk of teratoma formation and the need for careful dosing regimens.

Interventions targeting proteostasis have demonstrated lifespan extension in multiple species. Rapamycin, which inhibits mTOR and induces autophagy, extends lifespan in mice, even when treatment begins late in life. This finding has been replicated across multiple laboratories, though the magnitude of effect varies by sex and genetic background. Spermidine supplementation has been shown to extend lifespan in yeast, worms, flies, and mice, with evidence suggesting autophagy-dependent mechanisms.

Evidence Limitations and Retractions

The evidence base for these hallmarks is substantial but not without limitations. Many foundational studies were conducted in single laboratories and have not been independently replicated. The field of aging research has faced challenges with reproducibility, particularly in studies of lifespan extension in model organisms. Some high-profile findings have been retracted or have received expressions of concern.

For example, a 2014 study by Ocampo et al. in Cell on in vivo reprogramming in mice has been cited extensively but has not been independently replicated in its entirety. More recently, concerns have been raised about the reproducibility of some epigenetic clock studies, particularly regarding the influence of technical artifacts on methylation measurements.

The field of proteostasis has seen retractions related to specific compounds. Some studies on resveratrol's effects on sirtuin activation and lifespan extension have been retracted or corrected. Researchers should exercise caution when interpreting individual studies and prioritize findings that have been replicated across multiple laboratories and model systems.

As of July 2026, no registered human clinical trials were identified that directly target genomic instability or epigenetic alterations as primary endpoints for aging interventions. A few clinical trials have examined rapamycin and its analogs (rapalogs) for aging-related outcomes, but these remain small and preliminary.

Safety Considerations

The interventions discussed in this article are experimental and have not been approved for human use. Safety profiles for most compounds targeting these hallmarks are incomplete. Rapamycin, for instance, is an FDA-approved immunosuppressant used in organ transplantation, but its chronic use in non-transplant populations raises concerns about immunosuppression, metabolic disturbances, and impaired wound healing.

Epigenetic modifiers such as HDAC inhibitors and DNA methyltransferase inhibitors are approved for certain cancers but carry significant toxicities, including cardiac arrhythmias, thrombocytopenia, and gastrointestinal effects. Their long-term safety in healthy individuals has not been established.

Partial reprogramming approaches carry inherent risks of tumorigenesis due to the oncogenic potential of Yamanaka factors, particularly c-MYC. Even transient expression of these factors has been associated with teratoma formation in animal models. Current research is focused on developing safer reprogramming protocols, but these remain experimental.

Senolytic compounds, which selectively eliminate senescent cells, have shown promise in preclinical models but have not been evaluated in long-term human studies. Concerns include potential effects on wound healing and tissue regeneration, as senescent cells play important physiological roles in these processes.

Current Research Status

Research on the hallmarks of aging is highly active and evolving rapidly. The field has moved from descriptive characterization of age-related changes to mechanistic studies and intervention development. Major areas of current investigation include:

• Development of senolytic therapies for age-related diseases
• Optimization of partial reprogramming protocols for epigenetic rejuvenation
• Identification of proteostasis enhancers suitable for chronic use
• Integration of multi-omics approaches to understand hallmark interactions
• Translation of findings from model organisms to human biology

The National Institute on Aging (NIA) and other funding agencies have prioritized research on aging mechanisms and interventions. The Interventions Testing Program (ITP) continues to evaluate potential lifespan-extending compounds in genetically heterogeneous mice, providing rigorous, multi-laboratory validation.

Frequently Asked Questions

How do genomic instability and epigenetic alterations relate to each other?

These processes are intimately connected. DNA damage can trigger local and global epigenetic changes through the recruitment of chromatin-modifying enzymes to repair sites. Conversely, epigenetic alterations can influence DNA repair efficiency by modulating chromatin accessibility. For example, heterochromatin loss with age exposes repetitive DNA elements to damage and recombination, while changes in DNA methylation can silence or activate DNA repair genes. The two hallmarks are best understood as interacting components of a larger aging network.

Can epigenetic aging clocks be used to measure biological age in humans?

Epigenetic clocks provide robust estimates of chronological age and are associated with mortality risk and age-related diseases. However, their ability to measure biological age—as distinct from chronological age—remains debated. While some interventions (e.g., caloric restriction) have been shown to slow epigenetic aging in animal models, evidence in humans is limited. The clocks are valuable research tools but are not yet validated for clinical use in individual health assessment.

What is the relationship between loss of proteostasis and neurodegenerative disease?

Loss of proteostasis is a central feature of many neurodegenerative diseases. The accumulation of misfolded protein aggregates—such as amyloid-beta plaques and tau tangles in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and huntingtin in Huntington's disease—is a pathological hallmark. Whether proteostatic decline is a primary cause or a consequence of these diseases remains unclear, but genetic evidence suggests that impaired proteostasis can directly contribute to disease risk. For example, mutations in autophagy genes have been linked to Parkinson's disease.

Are there any approved drugs that target these hallmarks of aging?

No drugs are currently approved specifically for targeting genomic instability, epigenetic alterations, or loss of proteostasis as aging interventions. Some existing drugs that modulate these pathways—such as metformin, rapamycin, and HDAC inhibitors—are approved for other indications (diabetes, immunosuppression, cancer) and are being investigated for repurposing in aging. However, their safety and efficacy for aging-related outcomes in healthy humans have not been established.

How do these hallmarks interact with other hallmarks of aging?

The hallmarks of aging are interconnected through multiple mechanisms. For example, genomic instability can trigger cellular senescence, which in turn promotes inflammation (a hallmark termed "inflammaging"). Epigenetic alterations can influence mitochondrial function and metabolic pathways. Loss of proteostasis contributes to stem cell exhaustion by impairing the maintenance of tissue-specific stem cells. Understanding these interactions is a major focus of current research, as interventions targeting a single hallmark may have broader effects through these network connections.

References

Hoeijmakers, J.H.J. (2009). "DNA damage, aging, and cancer." New England Journal of Medicine, 361, 1475-1485.

Horvath, S. (2013). "DNA methylation age of human tissues and cell types." Genome Biology, 14, R115.

López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., & Kroemer, G. (2013). "The hallmarks of aging." Cell, 153, 1194-1217.

López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., & Kroemer, G. (2023). "Hallmarks of aging: An expanding universe." Cell, 186, 243-278.

Ocampo, A., Reddy, P., Martinez-Redondo, P., et al. (2016). "In vivo amelioration of age-associated hallmarks by partial reprogramming." Cell, 167, 1719-1733.e12.

Hayflick, L., & Moorhead, P.S. (1961). "The serial cultivation of human diploid cell strains." Experimental Cell Research, 25, 585-621.

Harrison, D.E., Strong, R., Sharp, Z.D., et al. (2009). "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature, 460, 392-395.

Eisenberg, T., Abdellatif, M., Schroeder, S., et al. (2016). "Cardioprotection and lifespan extension by the natural polyamine spermidine." Nature Medicine, 22, 1428-1438.

Research-Only Disclaimer

The information presented in this article is for educational and scientific research purposes only. The compounds and interventions discussed are not approved by the FDA, EMA, or any other regulatory authority for human consumption or therapeutic use. Volta Peptides sells peptides and research compounds exclusively for laboratory research purposes. Nothing in this article should be construed as medical advice, a recommendation for self-administration, or an endorsement of off-label use. Researchers are advised to consult relevant safety data sheets and institutional guidelines before handling any research compounds. For more information, please refer to our Research Disclaimer and Quality & Testing pages.

Reviewed by the Volta Peptides Research Team